Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

EUROPEAN shares closed little changed on Tuesday in cautious trade as investors awaited the outcome of the second day of ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV ...

(Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...